Read More Pharma Industry News How Hansa Biopharma’s imlifidase could redefine access for hardest-to-match transplant candidates Hansa Biopharma seeks FDA approval for imlifidase to expand transplant eligibility in high-risk ESRD patients. See what this filing means for U.S. access. byPallavi MadhirajuDecember 22, 2025